Neuphoria Therapeutics (NEUP) Change in Receivables (2023 - 2026)
Neuphoria Therapeutics (NEUP) reported Change in Receivables of $495432.0 for Q1 2026, up 4616.66% year-over-year from $10503.9 in Q1 2025, and down 55.29% on a QoQ basis from $1.1 million in Q4 2025.
Neuphoria Therapeutics (NEUP) has 4 years of Change in Receivables data on file, last reported at $495432.0 in Q1 2026.
- Quarterly Change in Receivables rose 4616.66% year-over-year to $495432.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 2048.77% YoY) and the FY2025 annual result came in at -$114936.0, up 61.59% from the prior year.
- Change in Receivables slipped to $495432.0 in Q1 2026 per NEUP's latest filing, from $1.1 million in the prior quarter.
- Across five years, Change in Receivables topped out at $1.1 million in Q4 2025 and bottomed at -$326992.0 in Q4 2023.
- The 4-year median for Change in Receivables is -$10190.0 (2025), against an average of $107204.8.
- The widest annual swing landed in 2024, when Change in Receivables plunged 167.22%; it then surged 4616.66% in 2026.
- Tracing NEUP's Change in Receivables over 4 years: stood at -$326992.0 in 2023, then surged by 75.41% to -$80399.0 in 2024, then surged by 1478.31% to $1.1 million in 2025, then tumbled by 55.29% to $495432.0 in 2026.
- Per Business Quant, the three latest NEUP Change in Receivables figures stand at $495432.0 (Q1 2026), $1.1 million (Q4 2025), and -$10190.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 208,524.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -39.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -1.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 110.42 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | 495,432.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 495,432.00 |
| Mar 31, 2026 | 495,432.00 |
| Dec 31, 2025 | 1.11 Mn |
| Dec 31, 2025 | 1.11 Mn |
| Sep 30, 2025 | -10,190.00 |
| Sep 30, 2025 | -10,190.00 |
| Jun 30, 2025 | -12,644.00 |
| Jun 30, 2025 | -12,644.00 |
| Mar 31, 2025 | -10,969.00 |
| Mar 31, 2025 | -10,969.00 |
| Dec 31, 2024 | -80,399.00 |
| Dec 31, 2024 | -80,399.00 |
| Sep 30, 2024 | -10,924.00 |
| Sep 30, 2024 | -10,924.00 |
| Jun 30, 2024 | 21,177.00 |
| Jun 30, 2024 | 21,177.00 |
| Mar 31, 2024 | -9,640.00 |
| Mar 31, 2024 | -9,640.00 |
| Dec 31, 2023 | -326,992.00 |
| Dec 31, 2023 | -326,992.00 |
| Sep 30, 2023 | 16,252.00 |
| Sep 30, 2023 | 16,252.00 |